Literature DB >> 25363618

Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A (H7N9): a cohort study.

Xiaoli Liu1, Yimin Zhang, Xiaowei Xu, Weibo Du, Kunkai Su, Chunxia Zhu, Yuemei Chen, Shuiying Lei, Shufa Zheng, Jianwen Jiang, Shigui Yang, Jing Guo, Li Shao, Qian Yang, Jiajia Chen, Lanjuan Li.   

Abstract

Avian influenza A (H7N9) is a severe disease with high mortality. Hypercytokinemia is thought to play an important role in the pathogenesis. This study was to investigate the efficiency of plasma exchange (PE) + continuous veno-venous hemofiltration (CVVH) on the removal of inflammatory mediators and their benefits in the management of fluid overload and metabolic disturbance. In total, 40 H7N9-infected patients were admitted to our hospital. Sixteen critically ill H7N9-infected patients received combination of PE and CVVH. Data from these 16 patients were collected and analyzed. The effects of PE + CVVH on plasma cytokine/chemokine levels and clinical outcomes were examined. H7N9-infected patients had increased plasma levels compared to healthy controls. After 3 h of PE + CVVH treatment, the cytokine/chemokine levels descended remarkably to lower levels and were maintained thereafter. PE + CVVH also benefited the management of fluid, cardiovascular dysfunction and metabolic disturbance. Of the 16 critically ill patients who received PE + CVVH, 10 patients survived. PE + CVVH decreased the plasma cytokine/chemokine levels significantly. PE + CVVH were also beneficial to the management of severe avian influenza A (H7N9).
© 2014 The Authors. Therapeutic Apheresis and Dialysis © 2014 International Society for Apheresis.

Entities:  

Keywords:  Avian influenza A; Cytokine; H7N9; Hemofiltration; Plasma exchange

Mesh:

Year:  2014        PMID: 25363618     DOI: 10.1111/1744-9987.12240

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  18 in total

1.  [Is the immune hyporesponsiveness of uremic patients a protective factor for severe COVID-19 pneumonia?]

Authors:  Enrique A Florit; Fritz Diekmann
Journal:  Nefrologia       Date:  2020-05-23       Impact factor: 2.033

2.  Impacts of age and gender at the risk of underlying medical conditions and death in patients with avian influenza A (H7N9): a meta-analysis study.

Authors:  Qinglin Cheng; Gang Zhao; Li Xie; Xuchu Wang
Journal:  Ther Clin Risk Manag       Date:  2018-09-06       Impact factor: 2.423

Review 3.  Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy.

Authors:  Sahar Balagholi; Rasul Dabbaghi; Peyman Eshghi; Seyed Asadollah Mousavi; Farhad Heshmati; Saeed Mohammadi
Journal:  Transfus Apher Sci       Date:  2020-11-02       Impact factor: 1.764

4.  Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.

Authors:  Donald C Vinh; Laurent Abel; Paul Bastard; Matthew P Cheng; Antonio Condino-Neto; Peter K Gregersen; Filomeen Haerynck; Maria-Pia Cicalese; David Hagin; Pere Soler-Palacín; Anna M Planas; Aurora Pujol; Luigi D Notarangelo; Qian Zhang; Helen C Su; Jean-Laurent Casanova; Isabelle Meyts
Journal:  J Clin Immunol       Date:  2021-06-08       Impact factor: 8.542

5.  [Management of COVID-19: the Zhejiang experience].

Authors:  Kaijin Xu; Hongliu Cai; Yihong Shen; Qin Ni; Yu Chen; Shaohua Hu; Jianping Li; Huafen Wang; Liang Yu; He Huang; Yunqing Qiu; Guoqing Wei; Qiang Fang; Jianying Zhou; Jifang Sheng; Tingbo Liang; Lanjuan Li
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-02-21

Review 6.  Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications.

Authors:  M A Haimei
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 3.512

Review 7.  Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Authors:  Bingwen Liu; Min Li; Zhiguang Zhou; Xuan Guan; Yufei Xiang
Journal:  J Autoimmun       Date:  2020-04-10       Impact factor: 7.094

Review 8.  Controversial treatments: An updated understanding of the coronavirus disease 2019.

Authors:  Cantong Zhang; Shaoying Huang; Fengping Zheng; Yong Dai
Journal:  J Med Virol       Date:  2020-04-10       Impact factor: 20.693

9.  Application of plasmapheresis for Covid-19 patients.

Authors:  Atakan Turgutkaya; İrfan Yavaşoğlu; Zahit Bolaman
Journal:  Ther Apher Dial       Date:  2020-07-11       Impact factor: 2.195

Review 10.  Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art.

Authors:  Yinhua Zhang; Yuanyuan Chen; Zhongji Meng
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.